Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMV/HIV-CAR T Cells in People Living With HIV
NCT06252402Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CMV/HIV-CAR T Cells in human immunodeficiency virus infection (HIV) (3 arms), sponsored by City of Hope. Primary endpoints: Dose Limiting Toxicities at 28 days and Toxicity profile at 28 days. Started Dec 2024; status: recruiting.
02
Drugs
CMV/HIV-CAR T Cells
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06252402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06252402.